Y-Intercept (HK)’s TG Therapeutics TGTX Stock Holding History

Y-Intercept (HK)’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,165	Closed	-$304K	–	2161
2026 Q1	$304K	Buy	+9,165	New	+$273K	0.01%	1375
2025 Q2	–	Sell	-16,939	Closed	-$668K	–	2008
2025 Q1	$668K	Buy	+16,939	New	+$570K	0.05%	576
2024 Q3	–	Sell	-35,244	Closed	-$627K	–	1796
2024 Q2	$627K	Buy	+35,244	New	+$562K	0.03%	722
2024 Q1	–	Sell	-18,577	Closed	-$317K	–	1753
2023 Q4	$317K	Buy	18,577 +4,933	+36%	+$57.3K	0.03%	795
2023 Q3	$114K	Buy	13,644 +445	+3%	+$6.2K	0.01%	958
2023 Q2	$328K	Buy	+13,199	New	+$341K	0.03%	735
2022 Q4	–	Sell	-33,234	Closed	-$197K	–	1342
2022 Q3	$197K	Buy	+33,234	New	+$218K	0.02%	826
2021 Q1	–	Sell	-17,908	Closed	-$947K	–	801
2020 Q4	$947K	Buy	+17,908	New	+$605K	0.4%	41

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Y-Intercept (HK)'s TGTX Position: Q2 2026 in Review

Y-Intercept (HK) sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 9,165 shares — an estimated $304K sold.

Y-Intercept (HK) first reported a position in TGTX in Q4 2020 and held it in 8 quarters. The position peaked at $947K in Q4 2020. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Y-Intercept (HK) reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 9,165 TG Therapeutics shares in Q2 2026, an estimated $304K.
Y-Intercept (HK) first reported a position in TG Therapeutics in Q4 2020 and held it in 8 quarters.
Y-Intercept (HK)'s TG Therapeutics position peaked at $947K in Q4 2020.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.